Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YCJ-02
- Development stage
- Preclinical
- Lead developer
- Oils4Cure
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intraperitoneal Injection
01
Overview
**YCJ-02** is an Oils4Cure preclinical botanical drug described as an antispastic and analgesic cannabis extract. It is being developed for **spasticity** and **neuropathic pain** in the context of leukodystrophies. The public pipeline description identifies it as a cannabinoid-based extract but does not disclose its chemical composition, specific cannabinoid constituents, molecular targets, route of administration, or formulation.
- Other names
- Antispastic/Analgesic cannabis extract
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on YCJ-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YCJ-02.